Protocol Ledger

NCT06668805 · Phase II · ACTIVE NOT RECRUITING

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

Interventional Phase II clinical trial protocol NCT06668805 sponsored by BioMarin Pharmaceutical in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-22 Enrollment: 30 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06668805
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)30 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06668805
Protocol FieldVerified Registry Value
NCT IdentifierNCT06668805
Consolidated Lead SponsorBioMarin Pharmaceutical
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment30 participants (ESTIMATED)
Registered Start Date2024-11-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06668805
Hospital Research SiteLocationSite Profile
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
Children's Hospital ColoradoAurora, COOpen Hospital Dossier ->
Children's National Medical CenterWashington D.C, DCOpen Hospital Dossier ->
Nicklaus Children's HospitalMiami, FLOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for BioMarin Pharmaceutical across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI